Moneycontrol
Get App
Last Updated : Feb 26, 2019 06:22 PM IST | Source: PTI

Lupin launches acne symptoms treatment tablets in US

The company has launched Minocycline Hydrochloride extended-release tablets USP in the strength of 55 mg, after receiving an approval from the USFDA.

Drug firm Lupin on February 26 said it has launched in the US Minocycline Hydrochloride extended-release tablets, used for treatment of inflammatory lesions of acne.

The company has launched Minocycline Hydrochloride extended-release tablets USP in the strength of 55 mg, after receiving an approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said.

As per IQVIA MAT December 2018 data, the product had annual sales of around $76.8 million in the US, Lupin said.

The product is a generic version of Medicis Pharmaceutical Corporation's Solodyn tablets in the same strength, it added.

The tablets are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older, it added.

Shares of Lupin closed at Rs 773.40 per scrip on BSE, down 0.41 per cent from the previous close.
First Published on Feb 26, 2019 06:11 pm
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant